WO2005037866A8 - IGG3 anti rhesus-D dans la lignee yb2/0 ayant une forte activite en phagocytose - Google Patents
IGG3 anti rhesus-D dans la lignee yb2/0 ayant une forte activite en phagocytoseInfo
- Publication number
- WO2005037866A8 WO2005037866A8 PCT/FR2004/002657 FR2004002657W WO2005037866A8 WO 2005037866 A8 WO2005037866 A8 WO 2005037866A8 FR 2004002657 W FR2004002657 W FR 2004002657W WO 2005037866 A8 WO2005037866 A8 WO 2005037866A8
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- line
- phagocytosis activity
- igg3 anti
- rhesus
- anti rhesus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006534803A JP2007533639A (ja) | 2003-10-16 | 2004-10-18 | 強い食作用活性を有するYB2/0細胞株の抗RHESUS−DIgG3 |
EP04817229A EP1675616A2 (fr) | 2003-10-16 | 2004-10-18 | Nouvelles igg3 utiles pour stimuler la phagocytose |
US10/575,218 US20070218052A1 (en) | 2003-10-16 | 2004-10-18 | Novel lgG3 Antibodies for Stimulating Phagocytosis |
AU2004281220A AU2004281220A1 (en) | 2003-10-16 | 2004-10-18 | IGG3 anti rhesus-D in the line YB2/0 having a high phagocytosis activity |
CA002542508A CA2542508A1 (fr) | 2003-10-16 | 2004-10-18 | Igg3 anti rhesus-d dans la lignee yb2/0 ayant une forte activite en phagocytose |
BRPI0415420-7A BRPI0415420A (pt) | 2003-10-16 | 2004-10-18 | igg3 úteis para estimular a fagocitose |
IL174949A IL174949A0 (en) | 2003-10-16 | 2006-04-11 | ANTI RHESUS-D IgG3 IN A YB2/0 CELL LINE HAVING A STRONG PHAGOCYTOSIS ACTIVITY |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0312087A FR2861078B1 (fr) | 2003-10-16 | 2003-10-16 | NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE |
FR0312087 | 2003-10-16 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2005037866A2 WO2005037866A2 (fr) | 2005-04-28 |
WO2005037866A3 WO2005037866A3 (fr) | 2005-07-21 |
WO2005037866A8 true WO2005037866A8 (fr) | 2006-06-01 |
Family
ID=34385205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2004/002657 WO2005037866A2 (fr) | 2003-10-16 | 2004-10-18 | Igg3 anti rhesus-d dans la lignee yb2/0 ayant une forte activite en phagocytose |
Country Status (9)
Country | Link |
---|---|
US (1) | US20070218052A1 (fr) |
EP (1) | EP1675616A2 (fr) |
JP (1) | JP2007533639A (fr) |
AU (1) | AU2004281220A1 (fr) |
BR (1) | BRPI0415420A (fr) |
CA (1) | CA2542508A1 (fr) |
FR (1) | FR2861078B1 (fr) |
IL (1) | IL174949A0 (fr) |
WO (1) | WO2005037866A2 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005053742A1 (fr) * | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicament contenant une composition a base d'anticorps |
FR2957598B1 (fr) | 2010-03-17 | 2015-12-04 | Lfb Biotechnologies | Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes |
FR3003171B1 (fr) * | 2013-03-15 | 2015-04-10 | Lab Francais Du Fractionnement | Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5496548A (en) * | 1987-09-18 | 1996-03-05 | National Blood Authority | Human anti-RH(D) monoclonal antibodies, cell lines and methods of use of antibodies in immunoassays |
BR9305557A (pt) * | 1992-06-26 | 1997-03-25 | Aetsrn | Anticorpos monoclonais humanos anti Rhesus-D e composiçao farmacêutica que os contém |
DE10001372A1 (de) * | 2000-01-14 | 2001-08-02 | Deutsches Krebsforsch | Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen |
FR2807767B1 (fr) * | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
US7605235B2 (en) * | 2003-05-30 | 2009-10-20 | Centocor, Inc. | Anti-tissue factor antibodies and compositions |
-
2003
- 2003-10-16 FR FR0312087A patent/FR2861078B1/fr not_active Expired - Fee Related
-
2004
- 2004-10-18 WO PCT/FR2004/002657 patent/WO2005037866A2/fr active Application Filing
- 2004-10-18 BR BRPI0415420-7A patent/BRPI0415420A/pt not_active IP Right Cessation
- 2004-10-18 CA CA002542508A patent/CA2542508A1/fr not_active Abandoned
- 2004-10-18 AU AU2004281220A patent/AU2004281220A1/en not_active Abandoned
- 2004-10-18 JP JP2006534803A patent/JP2007533639A/ja active Pending
- 2004-10-18 EP EP04817229A patent/EP1675616A2/fr not_active Withdrawn
- 2004-10-18 US US10/575,218 patent/US20070218052A1/en not_active Abandoned
-
2006
- 2006-04-11 IL IL174949A patent/IL174949A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2005037866A3 (fr) | 2005-07-21 |
FR2861078A1 (fr) | 2005-04-22 |
WO2005037866A2 (fr) | 2005-04-28 |
FR2861078B1 (fr) | 2007-09-21 |
US20070218052A1 (en) | 2007-09-20 |
IL174949A0 (en) | 2006-08-20 |
EP1675616A2 (fr) | 2006-07-05 |
AU2004281220A1 (en) | 2005-04-28 |
CA2542508A1 (fr) | 2005-04-28 |
JP2007533639A (ja) | 2007-11-22 |
BRPI0415420A (pt) | 2006-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006066568A3 (fr) | Anticorps | |
WO2004099249A3 (fr) | Variants fc optimises et leurs procedes de generation | |
WO2004029207A3 (fr) | Variants fc optimises et methodes destinees a leur generation | |
WO2005092390A3 (fr) | Conjugues d'amidon d'hydroxyalkyle et d'une proteine | |
WO2006096491A3 (fr) | Compositions d'anticorps anti-ctla-4 | |
WO2003062375A3 (fr) | Stabilisation de polypeptides exposes à l'uree | |
EP2216046A3 (fr) | Anticorps anti-glypican 3 | |
WO2007120334A3 (fr) | Méthodes et compositions de ciblage de la polyubiquitine | |
WO2007147122A3 (fr) | Anticorps monoclonaux qui reconnaissent sélectivement des composés de méthamphétamine et de type méthamphétamine | |
WO2007008943A3 (fr) | Proteines optimisees qui ciblent la molecule ep-cam | |
WO2007129895A3 (fr) | Anticorps monoclonal antagoniste anti-cd40 humain | |
WO2006014683A3 (fr) | Immunoglobulines contenant principalement une glycoforme gal2glcnac2man3glcnac2 | |
WO2003100033A3 (fr) | Anticorps anti-$g(a)v$g(b)6 | |
WO2008079995A3 (fr) | Conjugué comprenant un peptide natriurétique et une région constante d'un anticorps | |
WO2006071856A3 (fr) | Immunoglobulines comprenant principalement une glycoforme man5glcnac2 | |
WO2007110678A3 (fr) | Anticorps neutralisants et procédés d'utilisation | |
AU2003259718A1 (en) | Methods for humanizing rabbit monoclonal antibodies | |
WO2006028936A3 (fr) | Molecules heteromultimeriques | |
AU2001268855A1 (en) | Single-domain antigen-binding antibody fragments derived from llama antibodies | |
WO2007044616A3 (fr) | Anticorps anti-cd30 optimises | |
WO2007002222A3 (fr) | Conjugues anticorps psma-medicament | |
WO2005080432A3 (fr) | Anticorps a regions hypervariables reparees | |
WO2004085478A3 (fr) | Proteines hybrides fc ameliorees | |
WO2001098358A3 (fr) | Compositions permettant d'identifier et d'isoler des cellules embryonnaires | |
WO2008043145A8 (fr) | Hybridomes produisant des anticorps dirigés contre le récepteur p2x7 non fonctionnel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 174949 Country of ref document: IL Ref document number: 2004817229 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2542508 Country of ref document: CA Ref document number: 2004281220 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006534803 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 2004281220 Country of ref document: AU Date of ref document: 20041018 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004281220 Country of ref document: AU |
|
CFP | Corrected version of a pamphlet front page |
Free format text: UNDER (54) PUBLISHED TITLE IN ENGLISH REPLACED BY CORRECT TITLE AND UNDER (57) PUBLISHED ABSTRACT IN ENGLISH REPLACED BY CORRECT ABSTRACT |
|
WWP | Wipo information: published in national office |
Ref document number: 2004817229 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0415420 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007218052 Country of ref document: US Ref document number: 10575218 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10575218 Country of ref document: US |